Switching to Aflibercept in Diabetic Macular Edema Not Responding to Ranibizumab and/or Intravitreal Dexamethasone Implant

Abstract : Purpose: To assess short-term functional and anatomical outcomes of refractory diabetic macular edema (DME) following a switch from ranibizumab or dexamethasone to aflibercept. Methods. We included retrospectively eyes with persistent DME after at least 3 ranibizumab and/or one dexamethasone implant intravitreal injections (IVI). The primary endpoint was the mean change in visual acuity (VA) at month 6 (M6) after switching. Results. Twenty-five eyes were included. Before switching to aflibercept, 23 eyes received a median of 9.5 ranibizumab, and among them, 6 eyes received one dexamethasone implant after ranibizumab and 2 eyes received only one dexamethasone implant. Baseline VA, before any IVI, was 52.9 ± 16.5 letters, and preswitch VA was 57.1 ± 19.6 letters. The mean VA gain was +8 letters () between preswitch and M6. The mean central retinal thickness was 470.8 ± 129.9 μm before the switch and 303.3 ± 59.1 μm at M6 (). Conclusion. Switching to aflibercept in refractory DME results in significant functional and anatomical improvement. The study was approved by the France Macula Federation ethical committee (FMF 2017-138).
Liste complète des métadonnées

Littérature citée [30 références]  Voir  Masquer  Télécharger

http://hal.upmc.fr/hal-01589903
Contributeur : Gestionnaire Hal-Upmc <>
Soumis le : mardi 19 septembre 2017 - 11:18:03
Dernière modification le : mercredi 21 mars 2018 - 18:57:40

Fichier

8035013.pdf
Publication financée par une institution

Licence


Distributed under a Creative Commons Paternité 4.0 International License

Identifiants

Collections

Citation

Antoine Herbaut, Franck Fajnkuchen, Lise Qu-Knafo, Sylvia Nghiem-Buffet, Bahram Bodaghi, et al.. Switching to Aflibercept in Diabetic Macular Edema Not Responding to Ranibizumab and/or Intravitreal Dexamethasone Implant. Journal of Ophthalmology, 2017, 2017, pp.80350130. 〈10.1155/2017/8035013〉. 〈hal-01589903〉

Partager

Métriques

Consultations de la notice

37

Téléchargements de fichiers

35